Showing posts with label effectiveness. Show all posts
Showing posts with label effectiveness. Show all posts

Saturday, August 21, 2010

The effectiveness of IPAB

For the first time, the Federal Government may bypass Congress and own Medicare cost containment policies to impose. This is the independent payment Advisory Board at least what the patient protection and affordable care Act promises, in establishing.

The action will start as far as the public concerned in 2014. January 15, 2014, and annually thereafter becomes IPAB recommendations to Congress to cut Medicare spending, if the CMS-Chief Actuary projects, CPI will grow faster than the average of the medical services CPI and urban consumers per capita expenditure (or 2019, the GDP growth rate plus one percent).If Congress or the IPAB's own expenditure reduction legislation six months passed must not, HHS recommendations implementieren.IPAB do also non-binding recommendations relating to other aspects of the Medicare and comprehensive national health care costs.

The IPAB process for recommend and imposing changes in Medicare provision in the first year (from 2013) by the Chief Actuary that exceeds growth of the CPI objectives that spanned three Jahre.Eine submission of recommendations follows in the second year, IPAB,



View the Original article

Sunday, July 18, 2010

A tale of two diseases: repair of comparative effectiveness research

Write in the New England Journal of Medicine (identification and removal of roadblocks to the comparative effectiveness research) share three authors, their experience in running a head-to-head study of AVASTIN (bevacizumab) versus Lucentis (ranibizumab), for wet age-related macular degeneration (AMD). Describe the barriers facing you and suggest that you need for comparative effectiveness research be removed

View the Original article